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Cryoglobulinaemic vasculitis is a complication of hepatitis
C virus (HCV) infection, responding to treatment with
pegylated interferon (peg-IFN)/ribavirin (RIB), but
vasculitis may first appear after treatment with peg-IFN/
RIB. A 35-year-old man with HCV infection presented to
our department with a 2-month history of a 3.3×3 cm
ulcer localised on the right shin, with a regular border,
on a violaceous base. Histopathological examination
revealed a leucocytoclastic vasculitis, rich in eosinophils.
The patient had been treated with peg-IFN/RIB
10 months prior and treatment was discontinued after
2 months because of the appearance of arthralgias and
neuropathy. Laboratory investigations revealed positive
cryoglobulins, elevation of rheumatoid factor and
reduction of C4 after treatment with peg-IFN/RIB.
Dressings with a hydrocellular foam were placed and
after 2 months the ulcer resolved. We presented this
case because of the rarity of development of a
cryoglobulinaemic vasculitis in a patient with HCV
infection, previously treated with peg-IFN/RIB.
BACKGROUND
Chronic hepatitis C virus (HCV) infection is one of
the most important causes of liver disease in the
world.1 Pegylated interferon (peg-IFN) plus riba-
virin (RIB), given for 24 or 48 weeks is a possible
treatment used in chronic HCV infection,1 achiev-
ing a higher sustained virological response rate.2
However, side effects are common and sometimes
severe, leading to discontinuation of treatment.1
Compared with IFN alone, the peg-IFN/RIB com-
bination treatment is associated with a higher inci-
dence of cutaneous side effects.3–5
Cryoglobulinaemic and non-cryoglobulinaemic
vasculitis are complications of HCV infection, and
mostly respond to antiviral treatment with
peg-IFN/RIB.1 3 However, vasculitis may also
worsen or even first appear under this antiviral
treatment, in spite of a good virological response to
peg-IFN/RIB.1 3
We report the case of a patient with chronic
HCV infection who developed leucocytoclastic vas-
culitis, with the presence of numerous eosinophils
and with peripheral neuropathy, after treatment
with peg-IFN/RIB.
CASE PRESENTATION
A 35-year-old man presented to our department
with a 2-month history of an ulcer localised on the
right shin. He was diagnosed with chronic
genotype 4 HCV infection of unknown aetiology
20 years prior, and had not been followed up in
hepatology consultation until 1 year previously. He
had been treated with a combination therapy with
peg-IFN 2a (180 mg/week) and RIB (1200 mg/day)
1 year earlier, but the treatment was discontinued
after 2 months because of the sudden appearance
of intense, peripheral arthralgias and peripheral
neuropathy, confirmed by electromyography. The
HCV viraemia changed from 700 000 to 540 UI/
mL at the end of treatment and the transaminases
normalised.
For maintaining the symptomatology, the patient
was medicated with pregabalin 75 mg/day, with
partial improvement of pain. He was referred to our
department for a 3.3×3 cm ulcer localised on his
right shin; it had a regular and elevated border on a
violaceous base, and granulation tissue was seen in
approximately 60% of the ulcer bed (figure 1).
INVESTIGATIONS
Laboratory investigations revealed positive cryoglo-
bulins and the persistence of HCV viraemia
(141 446 UI/mL). The rheumatoid factor was mark-
edly elevated (2600, normal <15) and C4 fraction
of complement was reduced (<5, normal 10–40)
after treatment with peg-IFN/RIB. The rest of the
biochemistry panel and haematological counts were
within normal limits, including hepatic transami-
nases. Histopathological examination of the border
of the ulcer revealed a leucocytoclastic vasculitis,
rich in eosinophils; it did not reveal granulomas
(figures 2 and 3).
Figure 1 Ulcer, localised on the right shin, 3.3×3 cm in
diameter, with a regular and elevated border, on a
violaceous base, and granulation tissue.
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TREATMENT
We suggested dressing the ulcer with hydrocellular foam, with a
fresh dressing placed every 5 days.
OUTCOME AND FOLLOW-UP
At 3 months of follow-up, the ulcer had almost healed (figure 4).
The patient maintains consultations with the gastroenterology
department for treatment of his HCV infection.
DISCUSSION
Chronic HCV infection may be complicated by the development
of vasculitis, which in most cases is attributed to the presence of
mixed cryoglobulinaemia,3 leading to an immune complex-type
vasculitis, predominantly involving small vessels.3 4 Vasculitis
occurs in <5% of cryoglobulinaemic patients and has a predi-
lection for patients with type II cryoglobulins.3
Our patient developed cryoglobulinaemic vasculitis and per-
ipheral neuropathy after treatment with peg-IFN/RIB.
The IFNs may cause new onset or exacerbation of vasculitis
in patients with HCV infection.1 Therefore, peg-IFN might
have been involved in the development of LCV in our patient.
Antiviral treatment with peg-IFN/RIB is the treatment of choice
for chronic HCV infection.1 3 Mixed cryoglobulins have been
identified in 40% of cases of HCV infection.3 4
However, few reported cases of exacerbation of cryoglobuli-
naemic vasculitis under therapy with IFN or peg-IFN/RIB have
been reported previously.3 4
The mechanisms involved in the uncommon harmful effects
of IFN on cryoglobulinaemia in patients with HCV infection
remain uncertain.4 According to the literature regarding
peg-IFN/RIB, peg-IFN is much more likely to be responsible for
vasculitis than RIB, but we could not prove it without a chal-
lenge test.5
In our case, the history of chronic HCV infection, depressed
levels of C4, positive cryoglobulins, the markedly elevation of
the rheumatoid factor and the sensory neuropathy of the legs,
after treatment with peg-IFN/RIB, suggest the diagnosis of cryo-
globulinaemic vasculitis. The participation of numerous eosino-
phils in the histology supports a medicamentous etiology for the
ulcer.4 5
There is no correlation between IFN or peg-IFN/RIB dose or
duration of treatment and the development of vasculitis.1 3
Symptoms may appear during treatment with peg-IFN/RIB or
after several months after treatment.1 3 In our patient, the
peg-IFN/RIB was discontinued 2 months after onset of treat-
ment in spite of a good virological response, because of the
appearance of peripheral arthralgias and peripheral neuropathy,
and a vasculitic ulcer on his right shin 2 months later.
Regarding neuropathy, factors other than vasculitis can lead
to neuropathic development, such as neurotoxic and antiangio-
genic effects of IFN, during peg-IFN/RIB treatment.3
Treatment of vasculitis related to IFN depends on the severity
of symptoms.3 5
In some cases of IFN-induced vasculitis, symptoms improve
spontaneously after discontinuation of IFN.3 In the presence of
severe or progressive symptoms, suggestive of irreversible
damage to vital organs, corticosteroids in combination with
cyclophosphamide therapy should be given.3 5
Figure 3 Histopathological examination of the border of the ulcer
revealed a leucocytoclastic vasculitis, rich in eosinophils (H&E, ×400). Figure 4 The ulcer, almost cured after 3 months of follow-up.
Figure 2 Histopathological examination of the border of the ulcer
revealed a leucocytoclastic vasculitis, rich in eosinophils (H&E, ×100).
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The safety of immunosuppressive treatment in patients with
chronic HCV infection is unknown,3 and systemic corticosteroids
could lead to increased viraemia in patients with HCV infec-
tion.1 3 6 Rituximab should be considered in patients with severe
vasculitis, peripheral neuropathy or glomerulonephritis.7 Our
patient did not undergo any systemic therapy, because the ulcer
resolved with a hydrocellular foam dressing changed every 5 days.
In recent years, peg-IFN/RIB combined with direct acting antivir-
als, such as sofosbuvir, or direct acting antiviral-combined therapy,
are the standard of care for HCV infection.8 9 Sofosbuvir belongs
to the nucleotide inhibitors of viral polymerase NS5B and acts as a
chain terminator during HCV replication.8 Regimens based on
direct-acting antivirals increase treatment efficacy and allow treat-
ment in peg-IFN-contraindicated patient populations.8 9
New treatment regimens to continue antiviral treatment
against HCV could avoid causing the skin complications asso-
ciated with peg-IFN.
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Learning points
▸ Chronic hepatitis C virus (HCV) infection may be complicated
by the development of vasculitis, which in most cases is
attributed to the presence of mixed cryoglobulinaemia.
▸ The interferons (IFNs) may cause new onset or exacerbation
of vasculitis in patients with HCV infection.
▸ There is no correlation between IFN or pegylated (peg) IFN/
ribavirin (RIB) dose or duration of treatment and the
development of vasculitis.
▸ Symptoms may appear during treatment with peg-IFN/RIB or
after several months after treatment.
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